|
|
||||||||
1 Franz Volhard Clinic and Max
Delbrück Center for Molecular Medicine, The atrial natriuretic peptide (ANP)-C
receptor is generally believed to clear ANP; however, the ANP-C
receptor may serve to reduce cAMP by inhibiting adenylate cyclase. ANP
decreases endothelial permeability in coronary endothelial cell
monolayers. We tested the hypothesis that part of this effect might be
mediated by the ANP-C receptor. We used an endothelial cell monolayer
from rat coronary endothelium and measured albumin flux. We applied either ANP or a ring-deleted ANP (C-ANP), which only stimulates the
ANP-C receptor. ANP and C-ANP both decreased permeability from 100 pM
to 100 nM by 60 and 30%, respectively. ANP increased endothelial cGMP
contents 5.5-fold, whereas C-ANP had no effect. ANP reduced endothelial
cAMP contents by 75%, which was only partly blocked by pertussis
toxin. C-ANP also reduced cAMP; however, this effect was completely
blocked by pertussis toxin. Protein kinase G inhibition blocked the
ANP-mediated decrease in permeability by 50%. In contrast,
pretreatment with pertussis toxin, in the face of protein kinase G
inhibition, blocked the effect completely. C-ANP decreased permeability
by half the amount of ANP. This C-ANP effect was completely blocked by
pertussis toxin but not by protein kinase G inhibition. Isoproterenol
(10 µM) increased permeability by almost 50%, which was completely
blocked by ANP but only partially blocked by C-ANP. The C-ANP effect
was blocked completely by pertussis toxin. Isoproterenol increased cAMP
threefold, which was abolished by ANP. C-ANP reduced the
isoproterenol-induced increase in cAMP by 50%. Isoproterenol had no
effect on cGMP. We conclude that agonist binding to the ANP-C receptor
inhibits cAMP production via a Gi
protein-coupled signaling system. This inhibition may contribute to the
decreased endothelial permeability evoked by ANP in this system.
atrial natriuretic peptide receptors; endothelial permeability; cGMP; cAMP
ATRIAL NATRIURETIC PEPTIDE (ANP) promotes natriuresis
and diuresis (26), inhibits renin and aldosterone release (8), and has
important effects on endothelial cell function (28, 30,
31). The effect on endothelial cell permeability is
variable and dependent on endothelial cell origin (19, 46, 48). ANP induces an increase in hematocrit in rats, even if they are
splenectomized and nephrectomized (16, 44, 47). In endothelial cell
monolayers from the bovine pulmonary artery, ANP increased permeability
via transcellular pathways (6, 46). In monolayers of rat coronary endothelial cells on the other hand, ANP reduced permeability while
increasing cGMP and reducing cAMP (16). ANP effects are mediated by
specific receptors. The ANP-A receptor and the ANP-B receptor are both
coupled to guanylate cyclase and produce cGMP (11, 12, 37). cGMP is an
activator of a cGMP-dependent protein kinase (14), which is intimately
involved in mediating the ANP-induced effects on endothelial cell layer
permeability (17). The ANP-C receptor is particularly abundant in the
kidney and is believed to be primarily responsible for clearing ANP
from the circulation (1, 29). However, not all authorities accept that
ANP-C receptors are silent. Stimulation of these receptors has been
reported to inhibit adenylate cyclase activity in platelets and
pheochromocytoma cells (2, 15), inhibit neurotransmission in autonomic
nerve terminals (15, 23), inhibit proliferation of cultured rat aortic
smooth muscle cells (10), and increase inositol phosphate in vascular
smooth muscle cells (20). Furthermore, ANP was shown to inhibit the
production and secretion of endothelin from cultured endothelial cells
via the ANP-C receptor (21). C-ANP is a ring-deleted ANP that only
binds to the ANP-C receptor (3). All three receptors have been
described in endothelial cells (1). We studied the role of the ANP-C
receptor in rat coronary endothelial cells by using the ring-deleted
C-ANP as a probe, and we compared the effects of ANP with those of
C-ANP. We found that ANP-C receptor occupancy induces detectable
effects on endothelial barrier function and that these effects rely on
a pertussis toxin-sensitive,
Gi-protein-coupled signaling
system distinct from that utilized by the ANP-A and ANP-B receptors.
Materials. Falcon plastic tissue
culture dishes were obtained from Becton Dickinson (Heidelberg,
Germany); Transwell polycarbonate filter inserts (24-mm diameter,
0.4-µm pore size) were from Costar (Bodenheim, Germany); fetal bovine
serum (FBS), newborn calf serum (NCS), medium 199, penicillin-streptomycin, and trypsin-EDTA were from GIBCO (Eggenstein,
Germany); ANP, C-ANP, KT5823, and pertussis toxin were from Calbiochem
(Bad Soden, Germany); and trypan blue, fatty acid-free albumin, and
isoproterenol were obtained from Sigma (Deisenhofen, Germany). All
other chemicals were of the best available quality, usually analytic grade.
Cell cultures. Coronary endothelial
cells were isolated from 250-g male Wistar rats and grown in culture as
previously described (35). Briefly, hearts were perfused with
collagenase, chopped, and dissolved into a suspension. From this
suspension, the fraction of endothelial cells was purified. Cells were
plated at a density of 106 cells
on 100-mm plastic petri dishes. The cells were cultured at 37°C in
medium 199 with Earle's salt, supplemented with 100 IU/ml penicillin
G, 100 µg/ml streptomycin, and 10% (vol/vol) NCS and 10% (vol/vol)
FBS. The medium was renewed every second day. After 5 days, when the
cells had grown to confluence, they were trypsinized in
phosphate-buffered saline [composed of (mM) 137 NaCl, 2.7 KCl,
1.5 KH2PO4,
and 8.0 Na2HPO4,
at pH 7.4, with 0.05% (wt/vol) trypsin and 0.02% (wt/vol) EDTA]
and seeded at a density of 7 × 104
cells/cm2 on either 24-mm round
polycarbonate filters or 60-mm plastic petri dishes for determination
of albumin flux, cAMP, and cGMP contents, respectively.
Experiments were performed with confluent monolayers, 4 days after the
cells were seeded on filters. As previously reported (18, 19, 35), the
purity of these cultures was >97% endothelial cells. The remaining
cell types in this preparation are primarily pericytes. Contamination
with vascular smooth muscle cells is not a factor in this preparation
(35).
Macromolecule permeability. The
permeability across the endothelial cell monolayer was studied in a
two-compartment system separated by a filter membrane (36, 38). Both
compartments contained modified Tyrode solution [composition of
(mM) 150 NaCl, 2.7 KCl, 1.2 KH2PO4,
1.2 MgSO4, 1.0 CaCl2, and 30.0 HEPES (pH 7.4, 37°C)] supplemented with 10% (vol/vol) NCS and 10%
(vol/vol) FBS. There was no hydrostatic pressure gradient between both
compartments. The "luminal" compartment containing the monolayer
had a volume of 2.5 ml, and the "abluminal" had a volume of 10.5 ml. The fluid in the abluminal compartment was constantly stirred.
Trypan blue-labeled albumin (50 µM) was added to the luminal
compartment. We precipitated the trypan blue-labeled albumin with HCl
and determined that no trypan blue was present in the supernatant by
means of photometry with two wavelengths. We were thus assured of
adequate binding to the albumin preparation. We had earlier employed
fluorescein isothiocyanate-labeled albumin (45) and compared this
method with trypan blue-albumin labeling. We found these methods to
give the same results. The appearance of trypan blue-labeled albumin in
the abluminal compartment was continuously monitored by pumping the
liquid through a two-wavelength photometer (Specord S10, Zeiss; Jena;
Germany; wavelength for measurement of trypan blue 580 nM, control
wavelength 720 nM). Increases of the concentration of trypan
blue-labeled albumin were detected with a time delay of <15 s. The
concentration of trypan blue-labeled albumin in the abluminal
compartment was determined every 10 min of incubation. The
concentration did not change significantly in the time frame of the experiments.
The albumin flux (F, expressed as
mol · s We used pertussis toxin (32), KT5823, and isoproterenol (45) in our
experiments at doses based on dose-response curves obtained in separate
preliminary experiments. We selected those doses providing a maximum
effect at a minimum concentration (data not shown). Pertussis toxin was
applied 2 h before the experiments. The monolayers were then washed by
a threefold medium change immediately before the experiments (32).
KT5823 was applied 30 min before the experiments.
Experimental protocols. The basic
medium used in these incubations was modified Tyrode solution as
described in Macromolecule permeability (pH 7.4 at 37°C) with 5% (vol/vol)
NCS and 5% (vol/vol) FBS. Determination of macromolecule permeability
and of cGMP and cAMP contents of the endothelial monolayers was started
after an initial equilibration period of 30 min, and then the basal albumin flux and cGMP and cAMP contents of each monolayer were determined for another 30 min of incubation. In one set of
experiments, monolayers were preincubated for 2 h in the presence
of 1 µg/ml pertussis toxin and then washed by a threefold medium
change. Afterwards, agents were added as indicated, and the response of the albumin flux and cGMP and cAMP contents were determined for an
additional 30 min.
The time course of the ANP-related effects on the endothelial monolayer
was determined in these studies in separate experiments over 1 h and
was similar to what we have observed previously. We observed that the
permeability effects were at a maximum by 30 min. The effects on cGMP
and cAMP were at a maximum by 10 min (data not shown). Thus the
functional permeability measurements were all made at 30 min, whereas
the second messengers were determined at 10 min in separate cell
experiments. The second messenger adjustments precede the functional
effects as shown by ourselves and others (19, 32, 45).
Extraction and assay of cellular cGMP and cAMP
contents. At the end of the incubations, the incubation
medium of the monolayer cultures was aspirated, ice-cold ethanol was
added to terminate the reactions, and the petri dishes were stored at
Reverse transcriptase-polymerase chain reaction for
ANP receptors. RNA was extracted from the cardiac
endothelial cells by the method of Chomczynski and Sacchi (13).
Isolated RNA (800 ng) were reverse transcribed into cDNA by Moloney
murine leukemia virus reverse transcriptase in a volume of 100 µl. cDNA (10 µl) was used to detect ANP-A, ANP-B,
ANP-C, and GAPDH, respectively in a PCR reaction by using specific
primer pairs. Ten microliters of 100 µl-PCR product were loaded per
lane and resolved in a 1.5% agarose gel.
Statistical analysis. Data are given
as means ± SD with n equaling six
experiments using independent cell preparations. Statistical analysis
of data was performed according to Student's unpaired t-test.
P values of <0.05 were considered significant.
Figure 1 shows the effect of ANP (Fig.
1A) and C-ANP (Fig.
1B) on albumin flux through the
endothelial monolayer. The measurements were made at 30 min, at which
time the responses had plateaued at a maximal level. ANP reduced
albumin flux in a dose-dependent manner until 1 µM was applied. At
that dose, the permeability-decreasing effect of ANP was blunted. C-ANP
also decreased permeability, albeit to a lesser degree. The effect was
also dose dependent until 1 µM was applied. Similar to the response
observed with ANP, the effect of C-ANP at this dose was also blunted.
The results indicate that both ANP and the C-ANP analog, the latter of
which only binds to the ANP-C receptor, reduced endothelial cell layer permeability.
![]()
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
1 · cm
2)
across the monolayer with the the surface area
S was determined from the rise of
albumin concentration
(d[A]2) during the
time interval dt in the abluminal
compartment (V, volume): F = d[A]2/dt × V/S, where t is time. To facilitate the
comparison of data obtained in the present study with those of other
studies, the permability coefficient (P, expressed as cm/s) (38) of the
combined system of monolayer and filter support can be calculated from
F as according to Fick's law of
diffusion as follows: P = F/([A]1
[A]2), where
[A]1 and [A]2 denote tracer
concentrations in the luminal and abluminal compartments, respectively.
Because the driving force
([A]1
[A]2) remained
virtually unchanged in the course of the described experiments, the
relative changes in F correspond to
similar changes in P. Values of
F were expressed as a percentage of a
defined control situation. The F data
are a percentage of control; 100% corresponds to albumin flux of 4.2 ± 0.4 × 10
13
mol · s
1 · cm
2
and a permeability coefficient of 5.37 ± 0.5 × 10
6 cm/s of barrier formed
by endothelial monolayer and filter support (32).
80°C. To determine the intracellular cGMP and cAMP contents,
the ethanol was evaporated at 60°C, and the samples were suspended
in double-distilled water, transferred into Eppendorf reaction tubes,
and centrifuged for 5 min at 14,000 g.
cGMP and cAMP concentrations in the supernatants were determined using
radioimmunoassays (Amersham, Braunschweig, Germany). The protein
contents of the samples were determined according to Bradford (7) using
bovine serum albumin as the standard.
![]()
RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

View larger version (31K):
[in a new window]

View larger version (37K):
[in a new window]
Fig. 1.
A: effect of atrial natriuretic
peptide (ANP) on albumin flux in endothelial cell monolayer. A
dose-related decrease in permeability is observed up to 100 nM. At 1 µM, the effect is blunted. B: effect
of ring-deleted ANP (C-ANP) on albumin flux in endothelial cell
monolayer. A dose-related decrease in permeability is observed up to
100 nM. At 1 µM, the effect is blunted. Thus ANP and C-ANP exert
similar effects on permeability, although that of ANP is stronger.
100% corresponds to permeability of 5.37 ± 0.5 × 10
6 cm/s of barrier formed
by endothelial monolayer and filter support. Data are means ± SD
after 30 min of incubation of n = 6 separate experiments. * P < 0.05 vs. control (C).
We performed dose-response curves of ANP and C-ANP on cAMP and cGMP, respectively, as shown in Table 1. ANP at 10 nM reduced cAMP. An optimal reduction was observed at 100 nM, whereas 1 µM had no additional effect. The results of C-ANP were similar; 100 nM had the greatest effect, whereas 1 µM increased the effect no further. ANP increased cGMP values in a dose-dependent manner up to 100 nM, after which a plateau was achieved. C-ANP had no effect on cGMP levels.
|
Figure 2 displays the changes in the second
messengers cGMP and cAMP in response to ANP (100 nM) or C-ANP (100 nM).
The measurements were made after 10 min. ANP (Fig.
2A) increased cGMP 5.5-fold. This
increase was not influenced by pertussis toxin (1 µl/ml at
2h). On
the other hand, ANP decreased cAMP levels by 75%. This decrease was
blunted by pertussis toxin. C-ANP (Fig.
2B) had no effect on cGMP
concentrations. On the other hand, C-ANP decreased cAMP by 35%. In the
presence of pertussis toxin, the effect was abolished. The data show
that ANP increased cGMP and reduced cAMP. C-ANP on the other hand had
no effect on cGMP but nonetheless reduced cAMP via a pertussis
toxin-sensitive mechanism.
|
Figure 3 shows the effect of ANP and C-ANP on endothelial cell layer permeability in the presence or absence of protein kinase G inhibitor (KT5823, 1 µM) or pertussis toxin. ANP (Fig. 3A) at 100 nM reduced the monolayer permeability by 60%. This reduction was blunted by half with the protein kinase G inhibitor KT5823 (1 µM). Pertussis toxin alone had no signifcant effect on the monolayer permeability. ANP after pertussis toxin pretreatment decreased permeability; however, the effect was blunted to values similar to those with KT5823 pretreatment. Pretreatment with both KT5823 and pertussis toxin totally eliminated the ANP-induced decrease in monolayer permeability. C-ANP (Fig. 3B) alone decreased albumin flux by 30%. This effect was not influenced by KT5823. However, in the presence of pertussis toxin, C-ANP no longer had an effect on endothelial permeability. These results indicate that the decrease in endothelial cell layer permeability induced by ANP is in part dependent on protein kinase G as well as on the function of a Gi protein responsible for reducing cAMP production.
|
We next performed a positive control experiment with isoproterenol (10 µM), as shown in Fig. 4.
2-Adrenoceptor stimulation is
known to increase endothelial cell layer permeability in rat coronary
endothelial cells via increased cAMP levels by activation of adenylate
cyclase (19). The increase in permeability induced by isoproterenol
(Fig. 4A) was abolished by ANP (100 nM). C-ANP (100 nM) reduced the isoproterenol-induced increase by 50%.
Isoproterenol increased cAMP threefold. ANP abolished this increase
completely. C-ANP reduced the increase in cAMP by 50%. Isoproterenol
alone had no effect on cGMP. ANP (Fig.
4B) increased cGMP by 5.5-fold, whereas C-ANP had no effect on cGMP. These results suggest that ANP
influences endothelial cell layer permeability via two distinct pathways. One pathway involves cGMP production, whereas the other pathway involves cAMP reduction.
|
Finally, we verified the presence of all three ANP receptors, namely, the ANP-A, ANP-B, and ANP-C receptors, on rat coronary endothelial cells. We used RT-PCR, and as can be seen in Fig. 5, all three receptor mRNAs were expressed in our cell preparation.
|
| |
DISCUSSION |
|---|
|
|
|---|
The important findings in this study were that the ANP-induced decrease in permeability of coronary artery endothelial cell monolayers may be mediated in part by the ANP-C receptor. The ANP-C receptor-mediated effect did not involve the production of cGMP but instead featured a reduction in cAMP. This reduction relied on a pertussis toxin-sensitive, Gi-protein-coupled signaling system distinct from that utilized by the ANP-A and ANP-B receptors. We also showed that the effect on permeability mediated by the ANP-A and ANP-B receptors was dependent on the action of protein kinase G. Inhibiting this enzyme blunted the ANP-mediated decrease in permeability, whereas inhibiting both protein kinase G and Gi-protein-coupled signaling abolished the effect completely. The decrease in permeability mediated by the ANP-C receptor was independent of protein kinase G. We included a positive control experiment in that we showed that ANP abolishes the increase in endothelial monolayer permeability induced by isoproterenol. The C-ANP analog, which only stimulates the ANP-C receptor, decreased the isoproterenol effect by 50%, again without the generation of cGMP. Our current results extend our earlier observations that cGMP and cAMP are functional antagonists in the control of macromolecular permeability of coronary endothelial monolayers (19). Here we show that activation of the ANP-C receptor leads to a reduction in cAMP, whereas activation of the ANP-A and ANP-B receptors leads to an increase in cGMP. Both effects work in concert to decrease the monolayer permeability.
We demonstrated that the ANP-C receptor is present on coronary
endothelial cells and showed that the ANP-C receptor is of functional
significance in these cells. Anand-Srivastava et al. (3) studied rat
aorta, brain striatum, anterior pituitary tissue, and adrenal cortical
membranes. They utilized the same ring-deleted analog of ANP, which is
only capable of stimulating the ANP-C receptor. In all of these
tissues, they showed that stimulation of this receptor reduced cAMP
generation by inhibiting adenylate cyclase. Furthermore, they
documented that the effect was pertussis toxin sensitive, implicating
an inhibitory guanine nucleotide regulatory protein. We are not the
first to show that the ANP-C receptor is present on endothelial cells.
Hu et al. (21) showed that ANP in doses similar to those that we
employed inhibits the production and secretion of endothelin from
cultured endothelial cells from bovine aorta. Pedram et al. (34)
recently demonstrated that natriuretic peptides inhibit
endothelin-stimulated vascular endothelial cell growth factor (VEGF)
production. The authors concluded that the ANP-C receptor was
responsible for mediating this effect because C-ANP, which binds only
to this receptor, was equally effective as ANP in this regard.
Furthermore, the ANP-mediated effect was not influenced by
administration of a cGMP inhibitor. Hutchinson et al. (22) presented
strong evidence that the ANP-C receptor is important to ANP-induced
growth inhibition of vascular smooth muscle cells. The importance of
the ANP-C receptor to the vascular wall was further shown by Kishimoto
et al. (24), who found that this receptor is transcriptionally
downregulated by
2-adrenergic
stimulation in vascular smooth muscle cells. These observations are of
interest from the fact that a
2-adrenergic agonist increased
endothelial permeability in our model, an effect that was attenuated in
part by occupancy of the ANP-C receptor.
We are aware that our in vitro model, showing that ANP induces a tightening or a lessened permeability of a cultured endothelial cell layer, rather than increasing endothelial barrier permeability, is a conundrum. Battle et al. (6) showed earlier that ANP increases the permeability of endothelial cells harvested from the pulmonary artery and that the effect involves the generation of cGMP. They further demonstrated that the increase in permeability involved membrane folding by light and scanning electron microscopy. Stelzner et al. (40) also studied pulmonary artery endothelial cell monolayers and found that by increasing cAMP concentrations, albumin transfer was decreased. Yonemaru et al. (48) studied unstimulated endothelial cell layers from bovine pulmonary artery endothelial cells and reported similar results. We have preliminary observations from pulmonary artery endothelial cells in accord with these findings. Nevertheless, in agonist-stimulated endothelial cell layers, with bradykinin or thrombin, for example (46), an increase in cGMP production serves to restore the endothelial barrier function to normal.
Tucker et al. (43) examined blood-tissue albumin transport after physiological ANP infusions in rats. They observed that filtration-dependent, tissue-selective increases in albumin transport occurred. Increased albumin clearance was shown in small intestine, colon, fat, kidney, and skeletal muscle; however, no increase was observed in skin, diaphragm, or lung. In the heart, an increase was observed only in the left ventricle at a high ANP infusion dose. Tucker (42) verified that endogenous ANP was responsible by performing atrial appendectomy in rats. We concentrated our interests on coronary artery endothelial cells, because we are particularly interested in coronary disease. The permeability decreases after ANP that we observed in the current study are in line with our previous report and also concur with endothelial monolayer studies of Westendorp et al. (46). We believe that endothelial cells from various tissue may differ in regard to ANP responses. Watanabe et al. (45) found that adenosine both increased and decreased endothelial monolayer permeability to protein. The direction was related to the origin of the cells. Sill et al. (39) showed that shear stress elevated monolayer permeability and found that dibutryl cAMP and phosphodiesterase inhibition blocked the effect. On the other hand, Kubes and Granger (25) observed an increase in the permeability index in cat and rat mesentery during nitric oxide synthesis blockade. Finally, Lofton et al. (27) found that glucose oxidase-induced increases in endothelial monolayer permeability to albumin were inhibited by pretreatment with ANP in doses similar to those we employed. The authors found that ANP reduced the changes in cell shape provoked by the oxidant. We believe that extrapolating these in vitro monolayer data to whole organs or organisms requires appropriate caution, particularly because we administered ANP in a pharmacological fashion and we are unable to state for certain what the meaning of our doses is in terms of ANP levels found in the circulation of living organisms.
We understand that extrapolating permeability of culture systems to an in vivo situation is problematic. The permeability of cultured monolayers is several orders of magnitude greater than that of intact microvessels (35). We nevertheless believe that our findings may be of clinical significance. Various natriuretic peptide genes are activated in failing and ischemic ventricles, including ANP (4). Takahashi et al. (41) provided data showing that the ventricular expression of B-type ANP, C-type ANP, and ANP mRNAs is concordantly regulated in patients with severe congestive heart failure. They suggested that this coexpression of these two natriuretic peptides may play a role in compensatory processes in heart failure; however, they did not go into detail on how natriuretic peptides may benefit failing or ischemic myocardium. We showed earlier that ANP protects against reoxygenation-induced hypercontracture in cardiomyocytes, suggesting a protective role of ANP in the presence of ischemia (18). Furthermore, Noll et al. (33) also found that depriving coronary endothelial monolayers of energy (ischemia) increases endothelial cell-layer permeability. Thus a second important protective effect of ANP may be related to the results reported here. Under the circumstances of ischemia and/or ventricular dysfunction, a decrease in endothelial permeability may assist in avoiding intercellular edema, increasing the barrier to O2 and CO2 exchange, and maintaining endothelial barrier function. Whereas the protective effects from ischemia in cardiomyocytes (18) appeared to depend exclusively on the generation of cGMP, the endothelial effects in the heart rely on both cGMP generation and cAMP inhibition.
That the inhibition of cAMP leads to a decrease in coronary endothelial cell-layer permeability was also shown in an earlier study involving neuropeptide Y (32). In that study, the neuropeptide Y effects were also influenced by pertussis toxin, implicating a Gi protein-sensitive pathway. Neuropeptide Y is released by adrenergic nerve endings that service the coronary arteries. The effects mediated by the ANP-C receptor were similar and suggest that neuropeptide Y and ANP may act in concert to reduce endothelial layer permeability in the heart. The importance of the cAMP downregulation was underscored by our experiments with isoproterenol. This agonist alone markedly stimulated adenylate cyclase and increased cAMP production in endothelial cells, resulting in increased permeability (19, 32). Cotreatment with C-ANP suppressed the isoproterenol-related effects by 50% and reduced the cAMP response accordingly. ANP suppressed the isoproterenol-related increase in permeability completely, indicating the additional role of cGMP generation in this process. The magnitude of the cGMP effect was demonstrated by the experiments involving the inhibition of protein kinase G, which abolished the cGMP-related effects.
Our data underscore the heterogeneity of endothelial cell function and the complexity of ANP-related effects on the endothelial barrier. In the heart, ANP appears to maintain the integrity of the endothelial barrier, both via a generation of cGMP, which is mediated by the ANP-A and ANP-B receptors, and via a decrease in cAMP, which is mediated by the ANP-C receptor. Our results implicate a role for the ANP-C receptor, which is not only present on endothelial cells but also capable of mediating important physiological effects. We suggest that this receptor is responsible for much more than merely clearing superfluous ANP from the circulation.
| |
ACKNOWLEDGEMENTS |
|---|
We greatly appreciate the excellent technical assistance rendered by Gabriele Franke.
| |
FOOTNOTES |
|---|
This work was supported by a grant-in-aid from the Deutsche Forschungsgemeinschaft to A. Hempel (He 2119/5-1) and to H. M. Piper (A14, SFB 249).
Address for reprint requests: F. C. Luft, Franz Volhard Clinic, Wiltberg Strasse 50, 13122 Berlin, Germany.
Received 7 October 1997; accepted in final form 3 August 1998.
| |
REFERENCES |
|---|
|
|
|---|
1.
Almeida, F. A.,
M. Suzuki,
R. M. Scarborough,
J. A. Lewicki,
and
T. Maack.
Clearance function of C receptors of atrial natriuretic factor in rats.
Am. J. Physiol.
256 (Regulatory Integrative Comp. Physiol. 25):
R469-R475,
1989
2.
Anand-Srivastava, M. B.,
J. Gutkowska,
and
M. Cantin.
The presence of atrial natriuretic factor receptors of ANF-R2 subtype in rat platelets. Coupling to adenylate cyclase/cyclic AMP signal-transduction.
Biochem. J.
278:
211-217,
1991.
3.
Anand-Srivastava, M. B.,
M. R. Sairam,
and
M. Cantin.
Ring-deleted analogs of natriuretic factor inhibit adenylate cyclase/cAMP-system.
J. Biol. Chem.
265:
8566-8572,
1990
4.
Arad, M.,
N. Zamir,
L. Horowitz,
T. Oxman,
and
B. Rabinowitz.
Release of atrial natriuretic peptide in brief ischemia-reperfusion in isolated rat hearts.
Am. J. Physiol.
266 (Heart Circ. Physiol. 35):
H1971-H1978,
1994
5.
Baron, D. A.,
C. E. Lofton,
W. H. Newman,
and
M. G. Currie.
Atriopeptin inhibition of thrombin-mediated changes in the morphology and permeability of endothelial monolayers.
Proc. Natl. Acad. Sci. USA
86:
3394-3398,
1989
6.
Battle, T.,
J. B. Michel,
and
B. Corman.
Effect of atrial natriuretic factor on the water permeability of endothelial cells.
Biochem. Biophys. Res. Commun.
185:
386-391,
1992[Medline].
7.
Bradford, M. M.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:
248-254,
1976[Medline].
8.
Brenner, B. M.,
B. J. Ballermann,
M. E. Gunning,
and
M. L. Zeidel.
Diverse biological actions of atrial natriuretic peptide.
Physiol. Rev.
70:
665-699,
1990
9.
Burnett, J. C. Coronary endothelial function in
health and disease. Drugs 3, Suppl. 1: 20-29, 1997.
10.
Cahill, P.,
and
A. Hassida.
Clearance receptor-binding atrial natriuretic peptides inhibit mitogenesis and proliferation of rat aortic smooth muscle cells.
Biochem. Biophys. Res. Commun.
179:
1606-1613,
1991[Medline].
11.
Chang, M.-S.,
D. G. Lowe,
M. Lewis,
R. Hellmiss,
E. Chen,
and
D. V. Goeddel.
Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases.
Nature
338:
78-83,
1989[Medline].
12.
Chinkers, M.,
D. L. Garbers,
M.-S. Chang,
D. G. Lowe,
H. Chin,
D. V. Goedel,
and
S. Schulz.
A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor.
Nature
338:
78-83,
1989.
13.
Chomczynski, P.,
and
N. Sacchi.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:
156-159,
1987[Medline].
14.
Diwan, A. H.,
W. J. Thompson,
A. K. Lee,
and
S. J. Strada.
Cyclic GMP-dependent protein kinase activity in rat pulmonary microvascular endothelial cells.
Biochem. Biophys. Res. Commun.
202:
728-735,
1994[Medline].
15.
Drewett, J. G.,
R. J. Ziegler,
and
G. J. Trachte.
Neuromodulatory effects of atrial natriuretic peptides correlate with an inhibition of adenylate cyclase but not an activation of guanylate cyclase.
J. Pharmacol. Exp. Ther.
260:
689-696,
1991
16.
Flückiger, J. P.,
B. Waeber,
G. Matsueda,
B. Delaloye,
J. Nussberger,
and
H. R. Brunner.
Effect of atriopeptin III on hematocrit and volemia of nephrectomized rats.
Am. J. Physiol.
251 (Heart Circ. Physiol. 20):
H880-H883,
1986.
17.
Heim, J. M.,
S. Kiefersauer,
H. J. Fulle,
and
R. Gerzer.
Urodilatin and beta-ANF: binding properties and activation of particulate guanylate cyclase.
Biochem. Biophys. Res. Commun.
163:
37-41,
1989[Medline].
18.
Hempel, A.,
M. Friedrich,
K. D. Schlüter,
W. G. Forssmann,
M. Kuhn,
and
H. M. Piper.
ANP protects against reoxygenation-induced hypercontracture in adult cardiomyocytes.
Am. J. Physiol.
273 (Heart Circ. Physiol. 42):
H244-H249,
1997
19.
Hempel, A.,
T. Noll,
A. Muhs,
and
H. M. Piper.
Functional antagonism between cAMP and cGMP on permeability of coronary endothelial monolayers.
Am. J. Physiol.
270 (Heart Circ. Physiol. 39):
H1234-H1271,
1996.
20.
Hirata, M.,
C.-H. Chang,
and
F. Murad.
Stimulatory effects of atrial natriuretic factor on phosphoinositide hydrolysis in cultured bovine aortic smooth muscle cells.
Biochim. Biophys. Acta.
1010:
346-351,
1989[Medline].
21.
Hu, R. M.,
E. R. Levin,
A. Pedram,
and
H. J. L. Frank.
Atrial natriuretic peptide inhibits the production and secretion of endothelin from cultured endothelial cells.
J. Biol. Chem.
267:
17384-17389,
1992
22.
Hutchinson, H. G.,
P. T. Trindade,
D. B. Cunanan,
C.-F. Wu,
and
R. E. Pratt.
Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells.
Cardiovasc. Res.
35:
158-167,
1997
23.
Johnson, B. B.,
G. J. Trachte,
and
J. G. Drewett.
Neuromodulatory effect of the atrial natriuretic factor clearance receptor binding peptide, cANP(4
23)-NH2 in rabbit isolated vasa deferentia.
J. Pharmacol. Exp. Ther.
257:
720-726,
1991
24.
Kishimoto, I.,
T. Yoshimasa,
S. Suga,
Y. Ogawa,
Y. Komatsu,
O. Nakagawa,
I. H. Itoh,
and
K. Nakao.
Natriuretic peptide clearance receptor is transcriptionally down-regulated by
2-adrenergic stimulation in vascular smooth muscle cells.
J. Biol. Chem.
269:
28300-28308,
1994
25.
Kubes, P.,
and
D. N. Granger.
Nitric oxide modulates microvascular permeability.
Am. J. Physiol.
262 (Heart Circ. Physiol. 31):
H611-H615,
1992
26.
Lang, R. E.,
H. Thoelken,
D. Ganten,
F. C. Luft,
H. Ruskoaho,
and
T. Unger.
Atrial natriuretic factor: a circulating hormone stimulated by volume loading.
Nature
314:
264-266,
1985[Medline].
27.
Lofton, C. E.,
D. A. Baron,
J. E. Heffner,
M. G. Currie,
and
W. H. Newman.
Atrial natriuretic peptide inhibits oxidant-induced increases in endothelial permeability.
J. Mol. Cell. Cardiol.
23:
919-927,
1991[Medline].
28.
Lum, H.,
and
A. B. Malik.
Regulation of vascular endothelial barrier function.
Am. J. Physiol.
267 (Lung Cell. Mol. Physiol. 11):
L223-L241,
1994
29.
Maack, T.,
M. Suzuki,
F. A. Almeida,
D. Nussenzveig,
R. M. Scarborough,
G. A. McEnroe,
and
J. A. Lewicki.
Physiological role of silent receptors of atrial natriuretic factor.
Science
238:
675-678,
1987
30.
MacMillan-Crow, L. A.,
J. E. Murphy-Ullrich,
and
T. M. Lincoln.
Identification and possible localization of cGMP-dependent protein kinase in bovine aortic endothelial cells.
Biochem. Biophys. Res. Commun.
201:
531-537,
1994[Medline].
31.
Needleman, P.,
E. H. Blaine,
J. E. Greenwald,
M. L. Michener,
C. B. Saper,
P. T. Stockmann,
and
H. E. Tolunay.
The biochemical pharmacology of atrial peptides.
Annu. Rev. Pharmacol. Toxicol.
29:
23-54,
1989[Medline].
32.
Noll, T.,
A. Hempel,
and
H. M. Piper.
Neuropeptide Y reduces macromolecule permeability of coronary endothelial monolayers.
Am. J. Physiol.
271 (Heart Circ. Physiol. 40):
H1878-H1883,
1996
33.
Noll, T.,
A. Muhs,
M. Besselmann,
H. Watanabe,
and
H. M. Piper.
Initiation of hyperpermeability in energy-depleted coronary endothelial monolayers.
Am. J. Physiol.
268 (Heart Circ. Physiol. 37):
H1462-H1470,
1995
34.
Pedram, A.,
R. Mahnaz,
R.-M. Hu,
and
E. R. Levin.
Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion.
J. Biol. Chem.
272:
17097-17103,
1997
35.
Piper, H. M.,
R. Spahr,
S. Mertens,
A. Krützfeldt,
and
H. Watanabe.
Microvascular endothelial cells from heart.
In: Cell Culture Techniques in Heart and Vessel Research, edited by H. M. Piper. Heidelberg, Germany: Springer, 1990, p. 158-177.
36.
Schaeffer, R. C.,
F. Gong,
and
M. S. Bitrick.
Restricted diffusion of macromolecules by endothelial monolayers and small-pore filters.
Am. J. Physiol.
263 (Lung Cell. Mol. Physiol. 7):
L27-L36,
1992
37.
Schulz, M.-S.,
S. Singh,
R. A. Bellet,
G. Singh,
D. J. Tubb,
H. Chin,
and
D. L. Garbers.
The primary structure of a plasma membrane guanylate cyclase demonstrates diversity within this new receptor family.
Cell
58:
1155-1162,
1989[Medline].
38.
Siflinger-Birnboim, A.,
P. J. Del Vecchio,
J. A. Cooper,
F. A. Blumenstock,
J. M. Shepard,
and
A. B. Malik.
Molecular sieving characteristics of the cultured endothelial monolayer.
J. Cell. Physiol.
132:
111-117,
1987[Medline].
39.
Sill, H. W.,
Y. S. Chang,
J. R. Artman,
J. A. Frangos,
and
J. M. Tarbell.
Shear stress increases hydraulic conductivity of cultured endothelial monolayers.
Am. J. Physiol.
268 (Heart Circ. Physiol. 37):
H535-H543,
1995
40.
Stelzner, T. J.,
J. V. Weil,
and
R. F. O'Brien.
Role of cyclic adenosine monophosphate in the induction of endothelial barrier properties.
J. Cell. Physiol.
139:
157-166,
1989[Medline].
41.
Takahashi, Z.,
P. D. Allen,
and
S. Izumo.
Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles.
Circ. Res.
71:
9-17,
1992
42.
Tucker, V. L.
Contribution of ANP to plasma protein escape during VE: effects of thiorphan and atrial appendectomy.
Am. J. Physiol.
271 (Regulatory Integrative Comp. Physiol. 40):
R610-R618,
1996
43.
Tucker, V. L.,
K. E. Simanonok,
and
E. M. Renkin.
Tissue-specific effects of physiological ANP infusion on blood-tissue albumin transport.
Am. J. Physiol.
263 (Regulatory Integrative Comp. Physiol. 32):
R945-R953,
1992
44.
Valentin, J. P.,
J. Ribstein,
and
A. Mimran.
Effect of nicardipine and atriopeptin on transcapillary shift of fluid and proteins.
Am. J. Physiol.
257 (Regulatory Integrative Comp. Physiol. 26):
R174-R179,
1989
45.
Watanabe, H.,
W. Kuhne,
P. Schwartz,
and
H. M. Piper.
A2-adenosine receptor stimulation increases macromolecule permeability of coronary endothelial cells.
Am. J. Physiol.
262 (Heart Circ. Physiol. 31):
H1174-H1181,
1992
46.
Westendorp, R. G. J.,
R. Draijer,
A. E. Meinders,
and
V. W. M. van Hinsbergh.
Cyclic-cGMP-mediated decrease in permeability of human umbilical and pulmonary artery endothelial cell monolayers.
J. Vasc. Res.
31:
42-51,
1994[Medline].
47.
Williamson, J. R.,
S. W. Holmberg,
K. Chang,
J. Marvel,
S. P. Sutera,
and
P. Needleman.
Mechanisms underlying atriopeptin-induced increases in hematocrit and vascular permeation in rats.
Circ. Res.
64:
890-899,
1989
48.
Yonemaru, M.,
K. Ishii,
F. Murad,
and
T. A. Raffin.
Atriopeptin-induced increases in endothelial cell permeability are associated with elevated cGMP levels.
Am. J. Physiol.
263 (Lung Cell. Mol. Physiol. 7):
L363-L369,
1992
This article has been cited by other articles:
![]() |
J. M. Dodd-o, M. L. Hristopoulos, K. Kibler, J. Gutkowska, S. Mukaddam-Daher, A. Gonzalez, L. E. Welsh-Servinsky, and D. B. Pearse The role of natriuretic peptide receptor-A signaling in unilateral lung ischemia-reperfusion injury in the intact mouse Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L714 - L723. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. Gower Jr, S. Premaratne, R. W. McCuen, A. Arimura, Q. McAfee, and M. L. Schubert Gastric atrial natriuretic peptide regulates endocrine secretion in antrum and fundus of human and rat stomach Am J Physiol Gastrointest Liver Physiol, April 1, 2003; 284(4): G638 - G645. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. Gower Jr., J. R. Dietz, R. W. McCuen, P. J. Fabri, E. A. Lerner, and M. L. Schubert Regulation of atrial natriuretic peptide secretion by cholinergic and PACAP neurons of the gastric antrum Am J Physiol Gastrointest Liver Physiol, January 1, 2003; 284(1): G68 - G74. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Carvajal, K. Aguan, L. P. Thompson, I. A. Buhimschi, and C. P. Weiner Natriuretic Peptide-Induced Relaxation of Myometrium from the Pregnant Guinea Pig Is Not Mediated by Guanylate Cyclase Activation J. Pharmacol. Exp. Ther., April 1, 2001; 297(1): 181 - 188. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |